Literature DB >> 7560665

Histochemical and functional characteristics of metachromatic cells in the nasal epithelium in allergic rhinitis: studies of nasal scrapings and their dispersed cells.

H Otsuka1, M Inaba, T Fujikura, M Kunitomo.   

Abstract

BACKGROUND: In allergic rhinitis, metachromatic cells in the nasal epithelium increase in number and are thought to play an important role in nasal allergic manifestation.
METHODS: To determine immunohistochemical and functional characteristics of the metachromatic cells, nasal scrapings and their dispersed cells from patients with perennial allergic rhinitis were studied.
RESULTS: Eighty-three percent of all metachromatic cells in dispersed cell preparations were tryptase-positive mast cells (MCT), 10% were tryptase-chymase-positive cells (MCTC), and 7% were negative (n = 10). The mean histamine chymase-positive cells (MCTC), and 7% were negative (n = 10). The mean histamine content per metachromatic cell was 1.9 +/- 2 pg. The histamine content and histamine release from nasal surface scrapings of patients sensitized with mite antigen were strongly correlated with the level of serum IgE antibody for mite antigen. The net histamine release from nasal scraping was antigen-dose-dependent (1:2 x 10(7) to 1:2 x 10(3) dilution), and the antigen stimulated release of up to 17% of cell-associated histamine within 5 to 7 minutes. Histamine release from nasal scrapings induced by calcium ionophore A23187 was up to 21% of cell-associated histamine within 2 to 4 minutes, but no histamine release was stimulated by compound 48/80, substance P, or poly-L-lysine. Histamine release from nasal scrapings was inhibited 46% (10(-5) mol/L) to 96% (10(-4) mol/L) by quercetin and 58% (10(-4) mol/L) to 72% (10(-3) mol/L) by sodium cromoglycate.
CONCLUSIONS: These findings show the predominant characteristics of mast cells in the nasal epithelium in allergic rhinitis, and this information may be useful in relation to a therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7560665     DOI: 10.1016/s0091-6749(95)70297-0

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

Review 1.  Complementary therapy in allergic rhinitis.

Authors:  Elena S Resnick; Brett P Bielory; Leonard Bielory
Journal:  Curr Allergy Asthma Rep       Date:  2008-04       Impact factor: 4.806

Review 2.  Integrative Medicine for Respiratory Conditions: Asthma and Chronic Obstructive Pulmonary Disease.

Authors:  Gloria Y Yeh; Randy Horwitz
Journal:  Med Clin North Am       Date:  2017-06-21       Impact factor: 5.456

3.  A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.

Authors:  Marco Folci; Giacomo Ramponi; Enrico Brunetta
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Isolation and phenotypic characterization of mucosal nasal lymphocytes by direct ex vivo analysis.

Authors:  Christin Wolfram; Claudia Rasche; Heike Audring; Michael Wahls; Margitta Worm
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-09-03       Impact factor: 2.503

Review 5.  Emerging Therapies in Chronic Spontaneous Urticaria.

Authors:  Taek Ki Min; Sarbjit S Saini
Journal:  Allergy Asthma Immunol Res       Date:  2019-07       Impact factor: 5.764

Review 6.  Common respiratory diseases.

Authors:  David Kilgore; Wadie Najm
Journal:  Prim Care       Date:  2010-06       Impact factor: 2.907

Review 7.  Acute Urticaria and Anaphylaxis: Differences and Similarities in Clinical Management.

Authors:  Luis Felipe Ensina; Taek Ki Min; Mara Morelo Rocha Félix; Carolina Tavares de Alcântara; Célia Costa
Journal:  Front Allergy       Date:  2022-04-15

8.  Quercetin and Resveratrol Differentially Decrease Expression of the High-Affinity IgE Receptor (FcεRI) by Human and Mouse Mast Cells.

Authors:  Syed Benazir Alam; Ashley Wagner; Steven Willows; Marianna Kulka
Journal:  Molecules       Date:  2022-10-08       Impact factor: 4.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.